Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib + Temozolomide in Newly Diagnosed Glioblastoma
NCT02152982Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2014
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of veliparib in glioblastoma (GBM), Gliosarcoma (GS), sponsored by National Cancer Institute. Started Dec 2014; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02152982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152982.